share_log

藥師幫:截至2024年6月30日止六個月中期業績公告

YSB: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024

HKEX ·  Aug 26 04:34

Summary by Moomoo AI

藥師幫股份有限公司(「本公司」)宣佈截至2024年6月30日止六個月的未經審計中期業績。期內,本公司收入達人民幣8,813.9百萬元,較去年同期增長10.6%。毛利增至人民幣881.7百萬元,增長7.9%,而期內利潤由去年同期的虧損人民幣3,176.6百萬元轉為盈利人民幣13.4百萬元。非國際財務報告準則下的經調整淨利潤為人民幣91.4百萬元,同比增長30.3%。總GMV達人民幣23,830百萬元,同比增長8.1%。本公司於報告期內業務持續保持高質量增長,並積極響應國家相關政策,以科技賦能院外市場主體,推動院外醫藥市場向高效率和高質量發展。報告期內,本公司未派發任何股息。
藥師幫股份有限公司(「本公司」)宣佈截至2024年6月30日止六個月的未經審計中期業績。期內,本公司收入達人民幣8,813.9百萬元,較去年同期增長10.6%。毛利增至人民幣881.7百萬元,增長7.9%,而期內利潤由去年同期的虧損人民幣3,176.6百萬元轉為盈利人民幣13.4百萬元。非國際財務報告準則下的經調整淨利潤為人民幣91.4百萬元,同比增長30.3%。總GMV達人民幣23,830百萬元,同比增長8.1%。本公司於報告期內業務持續保持高質量增長,並積極響應國家相關政策,以科技賦能院外市場主體,推動院外醫藥市場向高效率和高質量發展。報告期內,本公司未派發任何股息。
Yao Shi Bang Co., Ltd. (the "Company") announces the unaudited interim performance for the six months ended June 30, 2024. During the period, the Company's revenue reached RMB 881.39 million, an increase of 10.6% compared to the same period last year. Gross profit increased to RMB 88.17 million, a growth of 7.9%, and the profit for the period turned from a loss of RMB 317.66 million in the same period last year to a profit of RMB 13.4 million. The adjusted net profit under non-international financial reporting standards was RMB 91.4 million, an increase of 30.3% compared to the same period last year. The total GMV reached RMB 2,383 million, an increase of 8.1% compared to the same period last year. The Company maintained high-quality growth during the reporting period and actively responded to relevant national policies, empowering technology to non-hospital market entities, and promoting the development of the non-hospital pharmaceutical market towards efficiency and high quality. During the reporting period, the Company did not distribute any dividends.
Yao Shi Bang Co., Ltd. (the "Company") announces the unaudited interim performance for the six months ended June 30, 2024. During the period, the Company's revenue reached RMB 881.39 million, an increase of 10.6% compared to the same period last year. Gross profit increased to RMB 88.17 million, a growth of 7.9%, and the profit for the period turned from a loss of RMB 317.66 million in the same period last year to a profit of RMB 13.4 million. The adjusted net profit under non-international financial reporting standards was RMB 91.4 million, an increase of 30.3% compared to the same period last year. The total GMV reached RMB 2,383 million, an increase of 8.1% compared to the same period last year. The Company maintained high-quality growth during the reporting period and actively responded to relevant national policies, empowering technology to non-hospital market entities, and promoting the development of the non-hospital pharmaceutical market towards efficiency and high quality. During the reporting period, the Company did not distribute any dividends.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more